NCT05052528View on ClinicalTrials.gov

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

May 15, 2025

Study Completion Date

December 15, 2025

Conditions
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given CD19 CAR T cells IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mehrdad Abedi, MD

OTHER

NCT05052528 - Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter